HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: tc.2007.022368v1 17/3/177    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Thavorn, K Articles by Chaiyakunapruk, N PubMed PubMed Citation Articles by Thavorn, K Articles by Chaiyakunapruk, N

A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand

¹ Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
² Department of Health Policy, Management, and Evaluation, University of Toronto, Ontario, Canada
³ Setting Priority Using Information on Cost-effectiveness Analysis, Ministry of Public Health, Thailand
⁴ School of Population Health, University of Queensland, Australia

Correspondence to:
Dr Nathorn Chaiyakunapruk, Department of Pharmacy Practice, Naresuan University, Phitsanulok 65000, Thailand; nui{at}u.washington.edu

Objective: To estimate the incremental cost-effectiveness ratio of a structured community pharmacist-based smoking cessation programme compared with usual care.

Design: A cost-effectiveness study using a healthcare system perspective

Population: Two simulated cohorts of smokers: male and female aged 40, 50 and 60 years who regularly smoke 10–20 cigarettes per day.

Intervention and comparator: A structured community pharmacist-based smoking cessation (CPSC) programme compared to usual care.

Main outcome measure: Cost per life year gained (LYG) attributable to the smoking cessation programme.

Results: The CPSC programme results in cost savings of 17 503.53 baht (£250; 325; $500) to the health system and life year gains of 0.18 years for men and; costs savings of 21 499.75 baht (£307; 399; $614) and life year gains of 0.24 years for women. A series of sensitivity analyses demonstrate that both cost savings and life year gains are sensitive to variations in the discount rate and the long-term smoking quit rate associated with the intervention.

Conclusion: From the perspective of the health system, the CPSC programme yields cost savings and life year gains. This finding provides important information for health policy decision-makers when determining the magnitude of resources to be allocated to smoking cessation service in community pharmacy.